DeepMed Research

WAKE FOREST UNIVERSITY HEALTH SCIENCES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Paricalcitol and Chemotherapy in Treating Women With Metastatic Breast Cancer

Phase 1

Completed

Conditions: Breast Cancer

Interventions: Drug: docetaxel
Drug: ixabepilone
Drug: paclitaxel
Drug: paclitaxel albumin-stabilized nanoparticle formulation
Drug: paricalcitol

First Posted Date: 2008-03-18

Last Posted Date: 2017-05-30

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 24

Registration Number: NCT00637897

Locations: 🇺🇸
Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States

Paricalcitol in Treating Patients With Advanced Prostate Cancer and Bone Metastases

Phase 2

Terminated

Conditions: Prostate Cancer
Metastatic Cancer

First Posted Date: 2008-03-13

Last Posted Date: 2018-07-06

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 2

Registration Number: NCT00634582

Locations: 🇺🇸
Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States

Healthy Living Partnership to Prevent Diabetes

Not Applicable

Completed

Conditions: Prediabetes
Obesity

Interventions: Behavioral: Group-Based Lifestyle Intervention (Phases 1 and 2)
Other: Individual Education Program (All Phases)
Behavioral: Self-Directed Maintenance (Phase 3)
Behavioral: Extended Group Maintenance (Phase 3)

First Posted Date: 2008-03-07

Last Posted Date: 2020-02-05

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 301

Registration Number: NCT00631345

Locations: 🇺🇸
Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States

Coronary Heart Disease as Measured by Coronary Calcium Score Among Individuals With Chronic Traumatic Spinal Cord Injury

Completed

Conditions: Heart Diseases
Spinal Cord Injuries

First Posted Date: 2008-03-05

Last Posted Date: 2022-04-21

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 45

Registration Number: NCT00628446

Locations: 🇺🇸
Carolinas Rehabilitation, Charlotte, North Carolina, United States

Utility of Amantadine Hydrochloride in the Treatment of Post-traumatic Irritability

Not Applicable

Completed

Conditions: Traumatic Brain Injury
Irritable Mood
Aggression

Interventions: Drug: Amantadine

First Posted Date: 2008-02-29

Last Posted Date: 2022-04-25

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 76

Registration Number: NCT00627250

Carbamazepine for the Treatment of Chronic Post-Traumatic Brain Injury Irritability and Aggression

Not Applicable

Completed

Conditions: Traumatic Brain Injury

Interventions: Drug: Placebo
Drug: Carbamazepine

First Posted Date: 2008-02-22

Last Posted Date: 2022-04-22

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 70

Registration Number: NCT00621751

Locations: 🇺🇸
Carolinas Rehabilitation, Charlotte, North Carolina, United States

Donor White Blood Cell Infusion in Treating Patients With Metastatic or Unresectable Cancer

Not Applicable

Withdrawn

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Unspecified Childhood Solid Tumor, Protocol Specific

First Posted Date: 2008-02-06

Last Posted Date: 2017-01-19

Lead Sponsor: Wake Forest University Health Sciences

Registration Number: NCT00607802

HDE Use Protocol of TheraSphere for Treatment of Unresectable HCC

Completed

Conditions: Hepatocellular Carcinoma

Interventions: Radiation: TheraSphere-Yttrium 90 microsphere

First Posted Date: 2008-01-30

Last Posted Date: 2022-04-22

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 11

Registration Number: NCT00605150

Erlotinib and Surgery in Treating Patients With Head and Neck Cancer That Can Be Removed by Surgery

Early Phase 1

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: erlotinib hydrochloride
Genetic: protein analysis
Genetic: western blotting
Other: immunohistochemistry staining method
Other: laboratory biomarker analysis
Other: liquid chromatography
Other: mass spectrometry
Procedure: neoadjuvant therapy
Procedure: therapeutic conventional surgery

First Posted Date: 2008-01-28

Last Posted Date: 2018-07-05

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 24

Registration Number: NCT00601913

Locations: 🇺🇸
Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States

Intensity-Modulated Radiation Therapy, Pemetrexed, and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck Cancer

Phase 1

Terminated

Conditions: Head and Neck Cancer

Interventions: Drug: erlotinib hydrochloride
Drug: pemetrexed disodium
Procedure: quality-of-life assessment
Radiation: intensity-modulated radiation therapy

First Posted Date: 2007-12-14

Last Posted Date: 2019-01-03

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 27

Registration Number: NCT00573989

Locations: 🇺🇸
Wake Forest University Comprehensive Cancer Center, Winston-Salem, North Carolina, United States
🇺🇸
UNC Linberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy